Articles related to ACUTE CORONARY SYNDROME (ACS)

Research shows that women account for 50% of MINOCA cases but only 25% of myocardial infarctions due to obstructive coronary artery disease, highlighting the importance of considering this diagnosis in female patients presenting with MI symptoms.

Multiple post-licensure studies have failed to demonstrate ticagrelor’s superiority over clopidogrel, prompting leading cardiologists to call for guideline reappraisal.

In a comprehensive Bayesian network meta-analysis, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a significant reduction in major bleeding compared to the conventional 12 months of DAPT, without an increase in MACCE.

In patients with chronic kidney disease, the elevated troponin challenge necessitates a nuanced approach, integrating serial measurements and clinical context to discern acute coronary syndrome from chronic elevations, thereby informing targeted management strategies.

Accelerate your understanding of thrombotic disease treatment developments; delve into the Fast Track designation of milvexian, a promising oral factor XIa inhibitor.

This study involved 566 men and women between the ages of 28 and 97 years, who were patients in a preventive cardiology practice. The PULS Cardiac Test measures multiple protein biomarkers, including hepatocyte growth factor, soluble Fas, and IL-16, and uses the results to calculate a five-year risk score for new ACS. All factors more than doubled their prior above the norm level. The 5-year ACS PULS risk score more than doubled as a result.